June 23, 2006 – Pfizer delivered one more setback to the sedative Indiplon, ending its collaboration with Neurocrine and returning all rights for Indiplon; Endo and Penwest received FDA approval for an oral, extended release form of oxymorphone; the FDA added an indication for glaucoma drug Lumigan from Allergan; Indevus began a Phase II trial of pagoclone for premature ejaculation; Abbott reported positive data on Humira for ankylosing spondylitis, an inflammatory disease of the spine; the German Merck stopped further development of sarizotan, a Parkinson’s disease drug; Johnson & Johnson will lay off 500 Scios workers; and Genzyme released positive data on Synvisc.The Centient Biotech 200™ rose 17 points to 3552.68, a gain of .48%. More details...
